Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase (Q46426194)

22 December 2017

title

Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase (English)

1 reference

22 December 2017

author name string

Komeno Y

1 reference

22 December 2017

Kurokawa M

1 reference

22 December 2017

Imai Y

1 reference

22 December 2017

Takeshita M

1 reference

22 December 2017

Matsumura T

1 reference

22 December 2017

Kubo K

1 reference

22 December 2017

Yoshino T

1 reference

22 December 2017

Nishiyama U

1 reference

22 December 2017

Kuwaki T

1 reference

22 December 2017

Kubo K

1 reference

22 December 2017

Osawa T

1 reference

22 December 2017

Ogawa S

1 reference

22 December 2017

Chiba S

1 reference

22 December 2017

Miwa A

1 reference

22 December 2017

Hirai H

1 reference

22 December 2017

publication date

1 June 2005

1 reference

22 December 2017

published in

Leukemia

1 reference

22 December 2017

volume

1 reference

22 December 2017

issue

1 reference

22 December 2017

page(s)

930-935

1 reference

22 December 2017

The roles of FLT3 in hematopoiesis and leukemia

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

The role of FLT3 in haematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

Oncogenic kinase signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

Efficient selection for high-expression transfectants with a novel eukaryotic vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

A new technique for the assay of infectivity of human adenovirus 5 DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

The structural basis for autoinhibition of FLT3 by the juxtamembrane domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

Juxtamembrane autoinhibition in receptor tyrosine kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

inferred from DOI database lookup

7 January 2021

based on heuristic

Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403736

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.LEU.2403736

1 reference

22 December 2017

1 reference

22 December 2017